BeyondSpring Inc. (NASDAQ:BYSI) Receives Average Rating of “” from Analysts
BeyondSpring Inc. (NASDAQ:BYSI) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price objective of $50.00 for the company and are anticipating that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 108 out of 265 based on the ratings given to related companies.
A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Rodman & Renshaw upped their price objective on shares of BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, July 14th. Finally, HC Wainwright set a $43.00 price objective on shares of BeyondSpring and gave the stock a “buy” rating in a research report on Wednesday, May 31st.
BeyondSpring (NASDAQ BYSI) traded up 4.28% during midday trading on Wednesday, reaching $40.00. The company’s stock had a trading volume of 1,458 shares. The stock’s 50 day moving average price is $39.34 and its 200-day moving average price is $30.30. The stock’s market cap is $868.28 million. BeyondSpring has a one year low of $16.55 and a one year high of $48.49.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.